TORONTO – May 3, 2021. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, Preclinical Research. Jeffrey will be responsible for advancing programs into IND-enabling studies, overseeing the discipline of experimental biology, and working with the leadership team on scientific and business strategies. Fueled by their AI drug discovery and development platform, called the AI Workbench, the company currently has ten programs in preclinical research.
"I'm excited that Jeffrey is joining our leadership team," said Brendan Frey, Ph.D., FRSC, Founder and Chief Executive Officer of Deep Genomics. "He is a proven leader with a strong background in RNA therapeutics for both neurological and metabolic disorders, which are closely aligned with our areas of focus, and in building bioinformatics capabilities. Jeffrey will be an important leader and mentor for our growing team of scientists and will bring critical insights to our corporate and portfolio strategies. I'm looking forward to working closely with him as we rapidly advance several existing preclinical programs, with plans to scale these efforts in the near term."
Dr. Brown commented, "I'm very impressed with Deep Genomics' AI Workbench, which is unlike anything I've seen in the industry. The capacity of the AI Workbench to generate targets and corresponding therapeutic molecules is remarkable, as is its ability to identify risks, allowing the team to advance preclinical programs and approaches with an increased likelihood of success toward development. I'm very much looking forward to working with Brendan and the team to continue to build a pipeline of RNA-based medicines to treat serious genetic diseases."
Dr. Jeffrey Brown is a seasoned biotech leader with deep experience in preclinical and IND-enabling research, with a particular focus on genetically-defined disorders and antisense oligonucleotides. He has worked across multiple therapeutic areas, including neuropsychiatry, neurodegeneration, neuromuscular diseases, and metabolic diseases. He has led more than 20 preclinical programs, successfully advancing a number of these into clinical development. Dr. Brown was most recently at Voyager Therapeutics, where he was responsible for building the research organization and leading multiple gene-therapy discovery research programs. Earlier, he was with Wave Life Sciences, where he led more than a dozen programs, several of which advanced to IND enabling studies. He also helped develop Wave's high-throughput screening capabilities and bioinformatics infrastructure. Prior to that, at Alexion, Dr. Brown was responsible for building the RNA therapeutics capabilities, including an RNA screening platform. He led a team at Alexion that successfully identified novel siRNA targets. He has held additional discovery and preclinical research roles with Bristol Myers Squibb, Pfizer, and Amgen. Dr. Brown earned his Ph.D. in Pharmacology and Toxicology at the University of Utah and was a postdoctoral research fellow at Harvard Medical School and then Boston University School of Medicine.
About Deep Genomics
Deep Genomics uses artificial intelligence and machine learning to program the best RNA therapies for almost any gene in any genetic condition. The platform, called the AI Workbench, enables Deep Genomics to decode vast amounts of data on RNA biology, identify novel targets for genetically defined disease, and produce therapeutic programs of the highest quality and that have a high rate of success. At some point in their life, everyone will face a genetic condition, and Deep Genomics aims to be there for them with a genetically precise therapy. Deep Genomics is located in Toronto, Canada and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow us on Twitter at @deepgenomics.